摘要
可手术切除Ⅱ-Ⅲa及Ⅲb(T3N2M0)期(IASLC/UICC第8版TNM分期)非小细胞肺癌(non-small cell lung cancer,NSCLC)推荐术后辅助化疗,但化疗毒性难以避免,且患者生存获益有限,仍具有较高的复发转移和死亡风险。在精准医疗时代,表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)开启个体化辅助治疗的新篇章。本文将对NSCLC术后辅助化疗、放疗、EGFR-TKI靶向治疗、抗血管生成治疗、免疫检查点抑制剂治疗及中医药治疗进行综述,多元化辅助治疗模式的探索有望延缓术后复发转移,使NSCLC患者生存获益最大化。
Complete resection of stageⅡ-Ⅲa andⅢb(T3N2M0)(IASLC/UICC TNM staging,the 8th edition)non-small cell lung cancer(NSCLC)is recommended for postoperative adjuvant chemotherapy,but chemotherapy toxicity is unavoidable,and survival benefits are limited,still have a high risk of recurrence,metastasis and death.In the era of precision medicine,targeted therapy with epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)has opened a new chapter in individualized adjuvant therapy.We focus on adjuvant chemotherapy,radiothera-py,EGFR-TKI targeted therapy,anti-angiogenesis therapy,immune checkpoint inhibitors and traditional Chinese medicine treatment to review.The exploration of diversified adjuvant therapy models is expected to delay postoperative recurrence and metastasis,and maximize the survival benefits of NSCLC patients.
作者
姜怡
刘苓霜
JIANG Yi;LIU Lingshuang(Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China)
出处
《现代肿瘤医学》
CAS
北大核心
2023年第3期552-556,共5页
Journal of Modern Oncology
基金
上海市卫生和计划生育委员会面上项目(编号:201840158)
上海申康医院发展中心新兴前沿技术联合攻关项目(编号:SHDC12018124)
上海市科学技术委员会科研项目(编号:19401971200)
刘嘉湘国医大师传承工作室建设项目(编号:DSGZS-2017002)。
关键词
非小细胞肺癌
完全性切除
辅助治疗
non-small cell lung cancer
complete resection
adjuvant therapy
